Revance Therapeutics Stock News

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual Meeting.

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance to Release Fourth Quarter and Full Year 2023 Financial Results on Wednesday February 28, 2024.

Revance Therapeutics, Inc. (NASDAQ:RVNC ) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Jessica Serra - Head, IR, Communications & ESG Mark Foley - CEO Dustin Sjuts

Although the revenue and EPS for Revance Therapeutics, Inc. (RVNC) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics co

Revance Therapeutics, Inc. stock has fallen by half in the past six months, despite impressive sales growth, prompting speculation on whether it is now a good buy. The recent DAXXIFY launch seems to b

The healthcare industry comprises multiple sectors, including biotechnology, pharmaceuticals, and healthcare equipment, each offering a unique and potentially risky opportunity. News regarding FDA app

After I spent many years following Wall Street, there are a few characteristics about the “big money”  that stand out for me. One of these traits is that many if not most large investors are very

Shares of Revance Therapeutics Inc. RVNC, -3.81% gained 8% premarket on Monday after the U.S. Food and Drug Administration approved the biotech company's Daxxify injection for treatment of cervical dy

The U.S. health regulator has approved expanding the use of Revance Therapeutics' Daxxify to treat a painful neck muscle condition, intensifying the anti-wrinkle injection's rivalry with AbbVie's Boto

Revance Therapeutics, Inc. (RVNC) came out with a quarterly loss of $0.80 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to loss of $0.88 per share a year ago.

Revance Therapeutics, Inc. (RVNC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street ana

Investing in healthcare stocks can be a wise decision for those looking to become wealthy in the long term. Some of the best healthcare stocks to buy are firms that are developing highly effective dr

Revance Therapeutics, a biotech stock, is at a 52-week high and reports earnings Tuesday. Their frown line treatment lasts longer than Botox.

We have narrowed our search to four stocks that are set to report earnings results today after market closes. These are: WYNN, CELH, RVNC and IAC.

Well-known investment advisor Ed Yardeni believes that U.S. stocks are poised to rally this year. Speaking to CNBC last week, Yardeni said that the banking mini-crisis will be “very well-contained�